ARTA
OCUL icon

A.R.T. Advisors’s Ocular Therapeutix OCUL Stock Holding History

A.R.T. Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-33,279
Closed -$132K – 1545
2019
Q1 		$132K Buy
33,279
+9,993
+43% +$40.2K 0.01% 1143
2018
Q4 		$93K Buy
23,286
+164
+0.7% +$904 0.01% 1171
2018
Q3 		$159K Buy
23,122
+5,300
+30% +$33.3K 0.01% 1230
2018
Q2 		$120K Buy
+17,822
New +$122K ﹤0.01% 1282
2017
Q4 		– Sell
-36,021
Closed -$222K – 1581
2017
Q3 		$222K Buy
36,021
+5,059
+16% +$32.6K 0.01% 1102
2017
Q2 		$287K Sell
30,962
-21,338
-41% -$207K 0.02% 1017
2017
Q1 		$485K Sell
52,300
-1,100
-2% -$9.16K 0.02% 817
2016
Q4 		$446K Buy
+53,400
New +$414K 0.03% 800
2016
Q3 		– Sell
-38,433
Closed -$190K – 1012
2016
Q2 		$190K Buy
+38,433
New +$381K 0.01% 1119
2016
Q1 		– Sell
-95,877
Closed -$898K – 1571
2015
Q4 		$898K Buy
+95,877
New +$1.04M 0.04% 617
2015
Q3 		– Sell
-67,399
Closed -$1.42M – 1517
2015
Q2 		$1.42M Buy
67,399
+8,307
+14% +$206K 0.05% 596
2015
Q1 		$2.48M Buy
+59,092
New +$1.94M 0.09% 313

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's OCUL Position: Q2 2019 in Review

A.R.T. Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2019, closing a stake of 33,279 shares — an estimated $132K sold.

A.R.T. Advisors first reported a position in OCUL in Q1 2015 and held it in 12 quarters. The position peaked at $2.48M in Q1 2015. 68 funds tracked by Wall St. Rank hold OCUL as of Q2 2019.

  • A.R.T. Advisors reported no remaining Ocular Therapeutix position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 33,279 Ocular Therapeutix shares in Q2 2019, an estimated $132K.
  • A.R.T. Advisors first reported a position in Ocular Therapeutix in Q1 2015 and held it in 12 quarters.
  • A.R.T. Advisors's Ocular Therapeutix position peaked at $2.48M in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.